A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
The purpose of this study is find out what effects, both good and bad, an experimental drug called entinostat has on you and your cancer, when given together with the standard hormonal drug treatment, exemestane. Exemestane is an aromatase inhibitor (drugs that lower estrogen) which is used in breast cancer patients to inhibit the growth of the breast cancer. In this study, you will take exemestane, and either entinostat or an inactive substance (placebo). Entinostat is investigational and has not been approved by the Food and Drug Administration (FDA) for use in this cancer. If you are male, you will also receive Goserelin, a luteinizing hormone releasing hormone (LHRH) agonist that is used to suppress the production of testosterone and estrogen.
Condition | Breast Cancer |
---|---|
Clinical Study Identifier | TX140449 |
Sponsor | Alliance |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.